Everest Organics (BSE 524790)₹254.95+2.39%Pharmaceuticals
In the Mar 2026 quarter (standalone), Everest Organics reported sales of ₹48.76 Cr, up 19.2% from Mar 2025, and net profit of ₹2.62 Cr, down 9.7% year on year. For the year to Mar 2026, sales were ₹196 Cr and net profit ₹5.98 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.68 | 49.48 | 52.56 | 52.58 | 32.46 | 44.08 | 42.03 | 40.91 | 53.83 | 51.03 | 42.60 | 48.76 |
| Expenses | 40.18 | 46.79 | 49.75 | 49.72 | 36.14 | 40.66 | 38.06 | 37.53 | 49.45 | 45.96 | 39.11 | 42.09 |
| Operating Profit | 2.51 | 2.70 | 2.79 | 2.94 | −3.65 | 3.42 | 4.01 | 3.43 | 4.43 | 5.12 | 3.53 | 6.68 |
| OPM % | 5.9% | 5.4% | 5.3% | 5.6% | −11.4% | 7.8% | 9.5% | 8.4% | 8.2% | 10.0% | 8.3% | 13.7% |
| Other Income | 0.21 | 0.23 | 0.12 | 0.29 | 0.32 | 0.13 | 0.00 | 0.21 | 0.54 | 0.28 | 0.24 | 0.15 |
| Interest | 1.30 | 1.50 | 1.46 | 1.25 | 1.30 | 1.36 | 1.41 | 1.16 | 1.32 | 1.24 | 1.24 | 2.77 |
| Depreciation | 1.28 | 1.31 | 1.32 | 1.84 | 1.46 | 1.46 | 1.46 | 1.55 | 1.51 | 1.51 | 1.51 | 1.92 |
| Profit before tax | 0.17 | 0.15 | 0.16 | 0.17 | −6.10 | 0.76 | 1.16 | 0.96 | 2.17 | 2.68 | 1.05 | 2.18 |
| Tax % | 75.1% | 78.7% | 93.4% | 62.6% | 0.0% | 1.3% | 0.9% | −206.3% | 35.3% | 57.0% | 65.5% | −21.1% |
| Net Profit | 0.03 | 0.02 | 0.01 | 0.05 | −6.07 | 0.73 | 1.13 | 2.90 | 1.40 | 1.15 | 0.35 | 2.62 |
| EPS (Rs) | 0.06 | 0.05 | 0.01 | 0.09 | −7.60 | 0.91 | 1.43 | 3.01 | 1.44 | 1.20 | 0.38 | 2.70 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 98.98 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 196 | 196 |
| Expenses | 94.16 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 176 | 177 |
| Operating Profit | 5.98 | 5.98 | 6.98 | 17.96 | 18.94 | 22.95 | 5.99 | 0.99 | 10.97 | 6.98 | 19.95 | 19.76 |
| OPM % | 5.9% | 6.0% | 5.9% | 10.9% | 10.9% | 12.9% | 3.2% | 0.5% | 6.0% | 4.5% | 10.0% | 10.1% |
| Other Income | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 6.98 | 0.99 | 0.99 | 0.99 | 1.21 |
| Interest | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 5.01 | 5.01 | 7.02 | 6.57 |
| Depreciation | 2.99 | 1.99 | 2.99 | 2.99 | 2.99 | 2.99 | 3.98 | 3.98 | 5.98 | 5.97 | 5.98 | 6.45 |
| Profit before tax | 0.00 | 2.01 | 2.01 | 12.02 | 14.02 | 17.02 | 2.01 | 0.00 | 1.01 | −3.01 | 8.01 | 8.08 |
| Tax % | 18.1% | 24.1% | 28.1% | 39.1% | 23.1% | 21.1% | 34.1% | 311.1% | 77.1% | −59.9% | 31.1% | — |
| Exceptional items | −0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.99 | 1.99 | 7.98 | 10.97 | 13.96 | 0.99 | 0.00 | 0.00 | −0.99 | 5.98 | 5.52 |
| EPS (Rs) | 0.55 | 1.70 | 2.13 | 9.40 | 13.63 | 17.16 | 1.41 | −0.21 | 0.19 | −1.34 | 5.71 | 5.72 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 11.0% | 7.0% | 9.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.98 | 2.99 | 7.98 | 7.97 | 7.98 | 7.97 | 7.98 | 7.98 | 7.98 | 7.98 | 9.97 | 9.98 |
| Reserves | −3.01 | 2.99 | 8.01 | 11.01 | 17.99 | 25.98 | 39.02 | 39.02 | 38.01 | 38.03 | 60.03 | 65.99 |
| Borrowings | 23.93 | 27.91 | 18.93 | 21.92 | 20.92 | 17.92 | 22.90 | 38.85 | 50.84 | 57.78 | 47.78 | 49.85 |
| Other Liabilities | 37.07 | 42.09 | 51.01 | 54.07 | 60.02 | 68.00 | 65.96 | 92.03 | 105 | 123 | 107 | 114 |
| Total Liabilities | 66.97 | 75.98 | 85.93 | 93.97 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 240 |
| Fixed Assets | 24.04 | 27.08 | 33.08 | 34.06 | 38.06 | 39.09 | 44.09 | 49.08 | 54.09 | 52.09 | 50.12 | 48.14 |
| CWIP | 0.00 | 0.99 | 0.99 | 0.99 | 0.00 | 0.99 | 0.00 | 7.99 | 11.97 | 20.95 | 22.95 | 20.96 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 41.93 | 46.91 | 51.86 | 59.92 | 67.85 | 79.79 | 91.77 | 121 | 136 | 153 | 152 | 171 |
| Inventories | 7.98 | 8.97 | 12.95 | 13.95 | 17.92 | 26.92 | 32.89 | 40.84 | 46.85 | 43.84 | 44.83 | 44.85 |
| Trade receivables | 28.93 | 31.90 | 30.92 | 37.89 | 40.89 | 43.85 | 50.87 | 68.75 | 75.78 | 99.70 | 87.78 | 116 |
| Cash & equivalents | 0.99 | 1.01 | 1.01 | 1.01 | 1.99 | 2.01 | 2.01 | 1.01 | 1.01 | 1.01 | 6.99 | 0.99 |
| Total Assets | 66.97 | 75.98 | 85.93 | 93.97 | 107 | 120 | 135 | 178 | 202 | 227 | 224 | 240 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 4.01 | 7.01 | 10.02 | 5.01 | 9.02 | 10.02 | 14.03 | 14.02 | 18.03 | 16.03 | −5.01 | 4.01 |
| Cash from investing activity | −3.01 | −7.01 | −8.01 | −4.01 | −5.01 | −6.01 | −12.02 | −17.02 | −16.01 | −13.02 | −5.01 | −2.01 |
| Cash from financing activity | −2.01 | 0.00 | −2.01 | −1.01 | −3.01 | −3.01 | −2.01 | 2.01 | −3.01 | −3.01 | 16.05 | −8.02 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | −1.01 | 0.00 | 0.00 | 6.01 | −6.01 |
| Capex | 2.78 | 6.98 | 7.60 | 3.47 | 7.21 | 7.20 | 6.87 | 17.18 | 13.56 | 13.13 | 5.44 | 3.25 |
| Free cash flow | 0.99 | 0.00 | 1.99 | 0.99 | 1.99 | 2.99 | 6.99 | −2.99 | 4.99 | 2.99 | −10.99 | 1.99 |
| CFO / OP % | 52.0% | 119.0% | 162.0% | 64.0% | 50.0% | 51.0% | 59.0% | 214.0% | 1,981.0% | 149.0% | −76.0% | 21.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 | 216 |
| Inventory days | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 166 | 133 |
| Days payable | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 351 | 264 |
| Cash conversion cycle | −41 | −64 | −84 | −56 | −25 | −13 | 28 | 23 | 8 | −12 | 16 | 84 |
| Working capital days | −29 | −37 | −49 | −33 | −14 | 8 | 22 | 10 | −11 | −19 | 4 | 28 |
| ROCE % | 19.1% | 11.1% | 13.1% | 13.0% | 35.1% | 35.1% | 34.1% | 6.0% | 4.0% | 6.0% | 2.0% | 12.0% |
For the Mar 2026 quarter, Everest Organics reported sales of ₹48.76 Cr, up 19.2% year on year and net profit of ₹2.62 Cr, down 9.7% year on year. The operating margin was 13.7%.
Everest Organics' sales for the year to Mar 2026 were ₹196 Cr; over the last twelve months they were ₹196 Cr.
Net profit for the year to Mar 2026 was ₹5.98 Cr, and ₹5.52 Cr over the last twelve months. Earnings per share over the same trailing period were ₹5.72.
Everest Organics reported borrowings of ₹49.85 Cr at Mar 2026, against cash and equivalents of ₹0.99 Cr.
Cash from operations was ₹4.01 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹1.99 Cr.